This multicenter, retrospective observational study will evaluate compliance an reasons for withdrawal in patients with moderate to severe active rheumatoid arthritis on treatment with intravenous RoActemra/Actemra (tocilizumab) in daily clinical practice. Data will be collected from each eligible patient over a period of 6 months.

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Moderate to severe rheumatoid arthritis according to the revised 1987 ACR criteria at baseline
• RoActemra/Actemra treatment must have been initiated 6 months prior to ICF signing
• Patient eligible according to the summary of product characteristics (SPC) and routine clinical practice/European recommendations for the use of biologic DMARDs for the treatment of rheumatoid arthritis

Exclusion Criteria:

• Rheumatic autoimmune disease other than RA
• Participation in interventional clinical trials during the observational period

Rheumatoid arthritis patients suitable for treatment with RoActemra/Actemra according to SPC